Corcept Therapeutics Incorporated CORT R3KPHARMA

Q: What is the current share price of Corcept Therapeutics Incorporated (CORT)?

As of 2026-09-19 21:16 PDT, Corcept Therapeutics Incorporated (CORT) trades at $113.98 on NasdaqCM. Its 52-week range is $32.15 to $123.57.

Q: What is the market capitalisation of CORT?

Corcept Therapeutics Incorporated (CORT) has a market capitalisation of $12.32B on NasdaqCM.

Q: What is the P/E ratio of CORT?

CORT trades at a trailing price-to-earnings (P/E) ratio of 259.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 17.69.

Q: What is the return on equity (ROE) of CORT?

CORT has a return on equity (ROE) of 8.23%. Its return on capital employed (ROCE) is 6.68%.

Q: Is CORT a good stock to buy?

This page provides a data-driven analysis of Corcept Therapeutics Incorporated (CORT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.corcept.com

Company Profile ↓

$113.98

+56.57% 1Y

Mkt Cap$12.32B

P/E259.05

P/B17.69

52W High$123.57

52W Low$32.15

Book Value$6.54

EPS (TTM)$0.44

Company Overview

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 118.8% CAGR over the past five years.

Healthy Margins

Operating margin of 16.1% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $761.41M (+12.8% YoY); net profit $99.65M.
Trailing 12 Months Year-on-year growth — revenue +31.7%, earnings +24.1%.
5-Year Trend Long-term compounding — revenue CAGR 118.8%, profit CAGR 1.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	118.75%
1 Year:	31.70%

Compounded Profit Growth

5 Years:	1.14%
1 Year:	24.10%

Stock Price Performance

1 Year:	+56.57%
6 Months:	+235.33%
3 Months:	+55.43%
1 Month:	+2.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 90% of range

$32.15 $123.57

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.82 · Neutral

Price Performance

1M+2.90%

3M+55.43%

6M+235.33%

1Y+56.57%

Valuation vs Sector

P/E of 259.05 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 118.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 259.1.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

259.05

Industry PE

24.83

Forward P/E

25.89

PEG Ratio

0.81

Book Value

$6.54

Price to Book

17.69

P/S

15.05

EV/EBITDA

1,487.17

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

118.75%

Profit 5Y

1.14%

Revenue (YoY)

31.70%

Earnings (YoY)

24.10%

Profitability & Returns

ROCE

6.68%

ROE

8.23%

ROA

0.47%

Profit Margin

6.64%

Op Margin

16.12%

Gross Margin

98.30%

EPS (Latest Qtr)

$0.36

EPS (TTM)

$0.44

Balance Sheet & Liquidity

Debt/Equity

1.33

Quick Ratio

2.50

Current Ratio

2.86

Debt

$9.42M

Total Assets

$888.70M

Current Assets

$485.46M

Working Capital

$319.38M

Ownership

Promoter Holding

11.45%

Chg in Prom Hold

0.01%

FII / Inst Holding

76.90%

Chg in FII Hold

-0.07%

Financial Snapshot

Enterprise Value

$12.32B

Total Revenue (TTM)

$830.81M

EBITDA

$8.08M

Free Cash Flow

$77.40M

Operating Cash Flow

$109.70M

Shares Outstanding

108.10M

Gross Margin

98.30%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CORT Corcept Therapeutics Incorporated R3KPHARMA	113.98	259.05	$12.32B	0.00%	6.68%	8.23%	118.75%	1.14%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	27.60M	35.56M	42.76M	53.28M	57.66M	62.31M	64.44M	66.83M	64.83M	72.26M	81.50M	87.89M	93.25M	88.56M	86.33M	85.73M	79.44M	91.59M	96.13M	93.69M	103.39M	101.73M	105.65M	117.72M	123.60M	146.81M	163.80M	182.55M	-	-	194.43M	207.64M	202.12M	164.90M	256.15M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.43M	4.60M	2.54M	2.88M	4.06M
Gross Profit	14.60M	15.66M	19.30M	21.06M	23.25M	26.95M	34.78M	41.79M	52.12M	56.48M	61.16M	63.14M	65.25M	63.59M	70.88M	80.05M	86.46M	91.37M	87.33M	85.11M	84.48M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	191.00M	203.04M	199.58M	162.02M	252.09M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	164.32M	192.82M	195.09M	211.62M	210.79M
Operating Income	-	592.00K	1.51M	3.07M	-	4.74M	12.79M	13.62M	-	21.00M	20.63M	22.97M	-	18.96M	24.63M	33.00M	-	37.71M	35.26M	24.72M	-	19.64M	31.94M	36.23M	26.77M	31.43M	31.93M	14.85M	29.58M	31.18M	29.50M	35.59M	46.60M	-	-	26.68M	10.22M	4.49M	-49.60M	41.30M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27.14M	10.70M	4.97M	-49.00M	42.16M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.69M	15.24M	9.91M	-44.72M	45.93M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.46M	-4.42M	-14.38M	-12.95M	2.94M
Net Income	959.00K	-19.00K	977.00K	2.58M	4.60M	4.39M	12.65M	13.76M	98.33M	17.46M	18.20M	17.75M	22.01M	18.27M	20.19M	26.34M	29.38M	30.07M	28.33M	21.62M	25.99M	23.46M	26.52M	30.47M	22.80M	27.41M	34.61M	15.88M	27.53M	31.38M	27.76M	35.49M	47.21M	-	-	35.15M	19.67M	24.29M	-31.76M	42.99M
Diluted EPS	-	-	0.01	0.02	-	0.04	0.10	0.11	0.77	0.14	0.14	0.14	0.18	0.15	0.17	0.22	0.24	0.25	0.23	0.17	0.20	0.18	0.21	0.24	0.20	0.24	0.30	0.14	0.25	0.28	0.25	0.32	0.41	-	-	0.29	0.16	0.20	-0.30	0.36
R&D Expense	-	4.63M	5.67M	7.05M	-	7.18M	7.88M	11.69M	-	17.05M	20.54M	18.86M	-	20.24M	21.66M	22.80M	-	26.12M	26.50M	33.87M	-	29.02M	28.23M	28.09M	28.12M	32.83M	33.29M	40.85M	43.28M	45.52M	58.51M	58.74M	59.34M	-	60.73M	60.47M	68.85M	-	66.27M	53.89M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	29.00K	-	-	3.31M	10.36M	26.55M	50.29M	81.32M	159.20M	251.25M	306.49M	353.87M	-	401.86M	482.38M	675.04M	761.41M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.38M	6.48M	10.88M	12.98M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	396.47M	475.89M	664.16M	748.43M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	283.84M	368.61M	527.21M	703.63M
Operating Income	-	-	-	-	-	-	-	-	-	-20.25M	-27.44M	-32.33M	-36.27M	-41.50M	-27.62M	-3.44M	10.18M	52.85M	89.50M	111.61M	128.20M	-	112.63M	107.28M	136.95M	44.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	116.08M	109.64M	138.29M	46.69M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	116.19M	124.56M	161.49M	66.46M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.77M	18.42M	20.28M	-33.19M
Net Income	-1.85M	-7.45M	-18.50M	-9.81M	-15.54M	-20.09M	-24.87M	-11.57M	-20.06M	-20.17M	-25.97M	-32.35M	-38.05M	-46.01M	-31.38M	-6.41M	8.14M	129.12M	75.41M	94.18M	106.01M	-	101.42M	106.14M	141.21M	99.65M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.06	0.07	1.04	0.60	0.77	0.85	-	0.87	0.94	1.23	0.82
R&D Expense	-	-	-	-	-	-	-	-	-	14.40M	18.95M	21.00M	14.07M	20.47M	18.37M	15.42M	23.84M	40.38M	75.25M	89.02M	114.76M	113.86M	130.99M	184.35M	246.89M	254.91M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 1999	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	-	-	-	-	-	-	-	-	-	25.10M	39.83M	99.17M	63.08M	34.63M	51.90M	68.75M	220.54M	311.69M	412.31M	571.73M	-	583.43M	621.52M	840.55M	836.65M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	499.25M	458.64M	471.60M	485.46M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	14.72M	23.87M	24.58M	39.63M	93.03M	54.88M	24.25M	40.44M	51.54M	31.06M	41.62M	31.27M	76.19M	-	66.33M	135.55M	127.67M	120.50M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.10M	7.73M	12.41M	12.87M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.06M	41.12M	53.98M	59.79M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	29.57M	35.81M	41.13M	48.39M	-	81.59M	114.81M	160.96M	188.85M
Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	3.86M	5.03M	8.36M	12.74M	13.55M	20.88M	27.37M	29.57M	35.57M	38.84M	47.49M	-	72.49M	104.50M	140.77M	166.09M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	29.03M	29.32M	24.46M	12.53M	0	0	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14M	151.00K	6.94M	6.11M
Total Equity	-244.00K	-2.00M	-7.54M	-21.94M	-31.47M	45.95M	26.59M	6.36M	14.73M	16.91M	22.09M	21.24M	34.81M	61.78M	21.02M	-3.39M	18.50M	41.38M	190.97M	275.88M	371.18M	523.34M	-	501.84M	506.70M	679.59M	647.80M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	130.96M	134.34M	137.75M	142.52M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-17.97M	-22.29M	-27.40M	-36.02M	-37.06M	-	-	18.39M	60.94M	115.67M	136.12M	151.97M	167.89M	120.32M	126.68M	198.29M	142.00M
Investing Cash Flow	3.59M	-	-25.00K	-151.00K	-127.00K	-	-	-194.00K	-73.46M	-90.77M	-117.83M	-119.26M	136.13M	-114.33M	90.91M	-177.60M	69.76M
Financing Cash Flow	23.52M	23.00M	42.48M	89.57M	-970.00K	-	-	-7.10M	-7.95M	-14.34M	-28.64M	12.21M	-302.59M	-17.28M	-148.72M	-28.35M	-220.37M
Capital Expenditure	-	-	-25.00K	-151.00K	-127.00K	-174.00K	-17.00K	-194.00K	-419.00K	-298.00K	-1.09M	-1.24M	-469.00K	-413.00K	-139.00K	-2.17M	-211.00K
Free Cash Flow	-	-	-27.43M	-36.17M	-37.19M	-	-	18.20M	60.52M	115.37M	135.03M	150.73M	167.42M	119.91M	126.54M	196.12M	141.78M
Share Buybacks	-	-	-	-	-	-	-	0	0	23.66M	30.98M	9.95M	-	0	0	15.66M	172.91M

Ratios (Annual)

Figures in %.

Metric	Dec 2000	Dec 2001	Dec 2002	Dec 2003	Dec 2004	Dec 2005	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	98.7%	98.7%	98.4%	98.3%
Operating Margin %	-	-	-	-	-	-	-	-	-	-69,827.6%	-	-	-1,096.8%	-400.7%	-104.0%	-6.8%	12.5%	33.2%	35.6%	36.4%	36.2%	-	28.0%	22.2%	20.3%	5.9%
Net Margin %	-	-	-	-	-	-	-	-	-	-69,537.9%	-	-	-1,150.5%	-444.3%	-118.2%	-12.7%	10.0%	81.1%	30.0%	30.7%	30.0%	-	25.2%	22.0%	20.9%	13.1%
ROE %	92.3%	98.9%	84.3%	31.2%	-33.8%	-75.6%	-391.1%	-78.5%	-118.7%	-91.3%	-122.2%	-93.0%	-61.6%	-218.9%	926.3%	-34.6%	19.7%	67.6%	27.3%	25.4%	20.3%	-	20.2%	20.9%	20.8%	15.4%
ROCE %	-	-	-	-	-	-	-	-	-	-	-129.2%	-92.9%	-39.9%	-82.4%	-131.1%	-11.1%	24.6%	27.7%	32.4%	29.9%	24.5%	-	22.0%	20.8%	19.6%	6.7%

Shareholding Pattern

Insiders

11.45%

Institutions

76.90%

Public Float

86.85%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	11.50%	12.43M	$1.37B
2	Ingalls & Snyder LLC	7.34%	7.93M	$875.10M
3	Renaissance Technologies, LLC	4.87%	5.26M	$580.30M
4	Vanguard Portfolio Management LLC	4.67%	5.04M	$556.37M
5	Vanguard Capital Management LLC	3.86%	4.17M	$460.18M
6	Parallel Advisors, LLC	3.67%	3.96M	$436.99M
7	FMR, LLC	3.09%	3.34M	$368.11M
8	State Street Corporation	3.03%	3.28M	$361.68M
9	AQR Capital Management, LLC	2.39%	2.58M	$284.83M
10	Geode Capital Management, LLC	2.34%	2.53M	$279.28M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CORT

Google News ue, 08 Sep 2026

Corcept: Not Cheap, But Backed By Real Structural Growth - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOcDAza1RiSklkVFFiS3VGeWJCcmhBZk5pdjVSX0NyOGRTU2xuZnhuR1o5bHBEa2JHSEExWVUwM1VySUZHZXhjMlR2dTlYZ014LWxpRE4xS1NyQVVpQlZlMFNJeV9qd1NwVFpiUlNVQXlwRWIxSWV1T3JFNUJ3VE8yWFJyeDBWQUt2R0VVeH…

Google News Fri, 04 Sep 2026

Insider Sale: See Remarks of $CORT Sells 11,730 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQRXFSUDFvMlgzOTJhSG9Yc1Y2QzI5SEZwUkM1aFlWUkkxcENlQWtHNlZBTzFrcnduR0lOZnh5U2hfbmtCcXluZE8tUy1ZZFIyOU1ramJOb0JoelNjNnp0dlc0WVNzRWlJcnB2YkEzbjZjM2FGNGUyNkVZYnhYRzVCdUFyWUlsb3E3MEFtND…

Google News Fri, 04 Sep 2026

Corcept (CORT) oncology president reports shares and 480K options - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQQkZuUDJ6SnFXalA2OXFBNUVELTFVVFVQR1pFOWxUaUt6aDBLejJEX3hXb3NTQnRQc2k3eU94S3MtOHhOM0ZXejdfMGV0dG1GU3pUV0k3RjFsekJvYk5qYzFGRVBmTEVtYld0eWNqVmpxY0huODNXdjJTTks3Wll3bElGVVN0YmthektiSj…

Google News Mon, 27 Jul 2026

Why Corcept (CORT) Stock Is Down Today - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNYjZpT0NnbjZ5OUEtLThZdXQtS0x3UlVKQVFuNXRBTXpSZnhRRTdoNUZ0MlJYb1IxVUtoQnFwYkJqd1pkOEtmQzVXSG45VGhFeVpZQWpraWhqTGpBVzFkODIwMjFqaVFrN1FTemp1MjFDMWtpSEpfTDlJMFQ3LUNEbTJOMVF0YVJCWTdNSW…

Google News Mon, 24 Aug 2026

Corcept Therapeutics Stock Climbs 11% On A 6-Day Winning Streak - Trefis

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUllpNTdaNVJDQllNNE1abnZYT2Zvay1JX3JBWWlHMjVHaTBwQjgyd1d1Z0wyOUJBc2daaVlkV1lvZ0FZSmtjSWhnMnhkS2dDbG9ya0JDUm96ZDUwNHhpZHM2Um9MclItRkpFMnUwbmNMZ0xvd0kySzNyQkRkcHhqbVJRVHRGeEFlYnkteE…

Google News Sat, 22 Aug 2026

Have Corcept Therapeutics Insiders Been Selling Stock? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxQYzJMWllXOWsxMHBEaUdiNDZ1UHRMSGgxYXJqMXJZQk1FZDNQbEtQdlpyTGRwcG9seWd5dHZFMzZ6THoyTDN5NXlGVXVKQUdsS2xSRlE4ZVBvTFZQSVRkbGRoYzl5TFdVeFpiVTZWR1hLRnZBUXVQTldzTWNxTjdYMDhlc3FIMDNtb1VOXz…

CORT — Frequently Asked Questions

What is the current share price of Corcept Therapeutics Incorporated (CORT)?

As of 2026-09-19 21:16 PDT, Corcept Therapeutics Incorporated (CORT) trades at $113.98 on NasdaqCM. Its 52-week range is $32.15 to $123.57.

What is the market capitalisation of CORT?

Corcept Therapeutics Incorporated (CORT) has a market capitalisation of $12.32B on NasdaqCM.

What is the P/E ratio of CORT?

CORT trades at a trailing price-to-earnings (P/E) ratio of 259.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 17.69.

What is the return on equity (ROE) of CORT?

CORT has a return on equity (ROE) of 8.23%. Its return on capital employed (ROCE) is 6.68%.

Is CORT a good stock to buy?

This page provides a data-driven analysis of Corcept Therapeutics Incorporated (CORT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Corcept Therapeutics Incorporated CORT R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Corcept: Not Cheap, But Backed By Real Structural Growth - Seeking Alpha

Insider Sale: See Remarks of $CORT Sells 11,730 Shares - Quiver Quantitative

Corcept (CORT) oncology president reports shares and 480K options - Stock Titan

Why Corcept (CORT) Stock Is Down Today - finance.yahoo.com

Corcept Therapeutics Stock Climbs 11% On A 6-Day Winning Streak - Trefis

Have Corcept Therapeutics Insiders Been Selling Stock? - simplywall.st

CORT — Frequently Asked Questions

What is the current share price of Corcept Therapeutics Incorporated (CORT)?

What is the market capitalisation of CORT?

What is the P/E ratio of CORT?

What is the return on equity (ROE) of CORT?

Is CORT a good stock to buy?

Explore More